This large population-based study compared breast-conserving surgery with radiation therapy (BCT) with mastectomy on (long-term) breast cancer-specific (BCSS) and overall survival (OS), and investigated the influence of several prognostic factors. Patients with primary T1-2N0-2M0 breast cancer, diagnosed between 1999 and 2012, were selected from the Netherlands Cancer Registry. We investigated the 1999-2005 (long-term outcome) and the 2006-2012 cohort (contemporary adjuvant systemic therapy). Cause of death was derived from the Statistics Netherlands (CBS). Multivariable analyses, per time cohort, were performed in T1-2N0-2, and separately in T1-2N0-1 and T1-2N2 stages. The T1-2N0-1 stages were further stratified for age, hormonal receptor and HER2 status, adjuvant systemic therapy and comorbidity. In total, 129,692 patients were included. In the 1999-2005 cohort, better BCSS and OS for BCT than mastectomy was seen in all subgroups, except in patients < 40 years with T1-2N0-1 stage. In the 2006-2012 cohort, superior BCSS and OS were found for T1-2N0-1, but not for T1-2N2. Subgroup analyses for T1-2N0-1 showed superior BCSS and OS for BCT in patients >50 years, not treated with chemotherapy and with comorbidity. Both treatments led to similar BCSS in patients <50 years, without comorbidity and those treated with chemotherapy. Although confounding by severity and residual confounding cannot be excluded, this study showed better long-term BCSS for BCT than mastectomy. Even with more contemporary diagnostics and therapies we identified several subgroups that may benefit from BCT. Our results support the hypothesis that BCT might be preferred in most breast cancer patients when both treatments are suitable.
treatment effects can be of additional value on outcomes obtained through RCTs. In these studies, treatment effects are evaluated in an unselected population making results more generalizable. 11 A recent observational population-based study of van Maaren et al. showed favorable overall (OS), relative (RS) and distant metastasis-free survival for BCT compared to mastectomy in T1N0 stage breast cancer. 12 Investigating the prognostic factors for survival in primary breast cancer, Saadatmand et al. showed that BCT led to significantly higher OS and RS than mastectomy (with or without radiation therapy, RT) in a Dutch cohort diagnosed between 1999 and 2012. 13 However, both of these studies lacked information about breast cancer-specific deaths and comorbidity.
The aim of this study was to investigate the effect of BCT compared to mastectomy on breast cancer-specific survival (BCSS) and OS. The prognostic factors age, stage, hormonal receptor status, HER2 status, adjuvant systemic therapy and comorbidity are considered as a possible explanation for the previously reported survival differences between BCT and mastectomy. To identify patients that could possible benefit from BCT, subgroup analyses were performed evaluating these prognostic factors separately in relation to BCSS and OS.
Methods

Study population
In this study, all patients diagnosed between 1999 and 2012 with primary T1-2N0-2M0 breast cancer treated with BCT or mastectomy were selected from the population-based Netherlands Cancer Registry (NCR). Details on the NCR are described elsewhere. 12, 13 In case of multiple breast surgeries, the most extensive surgery was used. T1-2N0-2M0 patients were included based on primary eligibility for both BCT and mastectomy. Patients with insufficient data for linkage of the NCR to the Statistics Netherlands (CBS) were excluded. Furthermore, patients who lacked information on type of surgery, clinical and pathological tumor stage or pathological nodal stage were excluded. Patients treated with primary (neoadjuvant) systemic therapy, breast-conserving surgery without RT, patients diagnosed with Paget's disease, ductal (DCIS) or lobular carcinoma in situ (LCIS) were excluded.
Procedures
Patient-, tumor-, and treatment-related characteristics were obtained from the NCR. Through linkage with the Municipal Personal Records database, data on vital status and date of death (if applicable) were obtained.
The cohort was divided into two prespecified consecutive time cohorts: the 1999-2005 cohort and the 2006-2012 cohort. The cohorts were chosen based on changes in the indication and type of systemic therapy available in daily practice, as described previously. 13 The 
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Study outcomes
The primary outcome was BCSS, the secondary outcome was OS. We compared BCT with mastectomy on both survival outcomes for the two cohorts separately: the 1999-2005 cohort and the 2006-2012 cohort.
Statistical analysis
For both the 1999-2005 and 2006-2012 cohorts, patient-, tumor-and treatment-related characteristics were compared between the treatment groups using the Pearson's X 2 or MannWhitney U tests. The Kaplan-Meier method was used to estimate crude BCSS, and the log-rank test was used to compare treatment groups. Hazard ratios (HR) with 95% confidence intervals (CIs) of BCT and mastectomy on both BCSS and OS were estimated using multivariable Cox proportional hazard analyses. These analyses were performed overall, and separately for the T1-2N0-1 stages (T1abN0, T1cN0, T1N1, T2N0, T2N1) and T1-2N2 stages. In addition, the T1-2N0-1 stages were further stratified according to age (<40, 40-49, 50-65, 66-75, > 75 years), hormonal receptor status (negative, positive), HER2 status (negative, positive), adjuvant systemic therapy administered (none, chemotherapy, endocrine therapy, both chemotherapy and endocrine therapy) and comorbidity at time of diagnosis (yes/no). In multivariable analyses, we adjusted for all potential confounding variables available for the specific time cohorts. The subgroup of patients < 40 years had too few events to study all potential confounding variables. For this subgroup, it was decided to use the most important prognostic factors based on foreknowledge (indicated in the legends of the figures). We tested the proportional hazard assumption by plotting all coefficients over time and inspecting these for consistency. No violations were found. All statistical tests were 
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two-sided and a p values < 0.05 was considered to be statistically significant. All analyses were performed in SPSS Statistics for Windows (version 21.0) (IBM Corp, Armonk, NY).
Results
The final study population consisted of 129,692 patients: 60,381 patients in the 1999-2005 cohort and 69,311 in the Table 1 and Supporting Information Table S1 . In the 1999-2005 cohort, the median age at diagnosis was 57 and 62 years in the BCT and mastectomy group, respectively. In the 2006-2012 cohort, the median age at diagnosis was 59 and 61 years for the BCT and mastectomy group, respectively. Characteristics of the subcohort with known comorbidity status are similar to the entire cohort, indicating its representativeness (Supporting Information Table S2 ). Information on adjuvant systemic therapy for both cohorts in the T1-2N0-1 stages is shown in Supporting Information Tables S3 and S4 . 1) . Median follow-up duration was 12.0 and 11.2 years for the BCT and mastectomy group, respectively. Kaplan-Meier analysis and the log-rank test showed significantly higher crude BCSS for BCT compared to mastectomy in T-2N0-1 and T1-2N2 stage (Fig. 2) . Overall, adjusted HRs for both BCSS [0.72 (95% CI: 0.69-0.76, p < 0.0001)] and OS [0.74 (95% CI: 0.71-0.76, p < 0.0001)] were higher for BCT than mastectomy. These results remained significant after stratification by T and N stage ( Fig. 3 and Supporting Information Table S5 ). Further stratification in T1-2N0-1 stage breast cancer for age category, systemic therapy and comorbidity showed similar superior survival for the BCT group (Fig. 4 and Supporting Information Table S6 ).
Breast cancer-specific and overall survival in the 2006-2012 cohort
In the BCT group, 3,702 out of 41,580 (8.9%) died, of whom 1,841 (49.7%) died due to breast cancer. In the mastectomy group, 5,504 out of 27,731 (19.8%) patients died, of whom 2,666 (48.4%) died due to breast cancer (Fig. 1) . Median follow-up duration was 6.0 and 5.9 years for the BCT and mastectomy group, respectively. Kaplan-Meier analysis accompanied by log-rank testing showed significantly superior crude BCSS for BCT compared to mastectomy in both the T1-2N0-1 and T1-2N2 stages (Fig. 2) .
After correction for confounding, adjusted BCSS and OS were superior for BCT compared to mastectomy in the entire cohort [0.75 (95% CI: 0.70-0.80, p < 0.0001)] and [0.67 (95% CI: 0.64-0.71, p < 0.0001)], respectively. This remained significant in the T1-2N0-1 stages (Fig. 3 and Supporting Information Table S5 ) but not in the T1-2N2 stages (Fig. 3 and Supporting Information Table S5 ).
Additional stratification within the T1-2N0-1 group showed superior BCSS and OS for patients >50 years, with comorbidity, without adjuvant systemic therapy and those treated with endocrine therapy only (Fig. 4 and Supporting Information Table S6 ). This superior outcome was present irrespective of hormonal receptor and HER2 status. No significant difference in BCSS was found between BCT and Figure 3 . Hazard ratios of breast-conserving therapy compared to mastectomy on BCSS for both cohorts, overall and specified for T and N stage. "T" indicates the tumor stage. "N" indicates the nodal stage. ¥Corrected for age, year of diagnosis, tumor stage, nodal stage, morphology, differentiation grade, axillary lymph node dissection, systemic therapy and contralateral breast cancer. §Corrected for age, year of diagnosis, morphology, differentiation grade, axillary lymph node dissection, systemic therapy and contralateral breast cancer. ¶Corrected for age, year of diagnosis, tumor stage, nodal stage, morphology, differentiation grade, axillary lymph node dissection, systemic therapy, contralateral breast cancer, hormonal receptor status, HER2 status and multifocality. ᭛Corrected for age, year of diagnosis, morphology, differentiation grade, axillary lymph node dissection, systemic therapy, contralateral breast cancer, hormonal receptor status, HER2 status and multifocality.
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Lagendijk et al. mastectomy in patients <50 years, patients without comorbidity and patients treated with adjuvant chemotherapy (Fig. 4 and Supporting Information Table S6 ). With regard to OS, no significant differences between treatments were found in patients aged < 40, and those treated with adjuvant chemotherapy (Fig. 4 and Supporting Information Table S6 ).
Discussion
BCT showed roughly 25% better BCSS and OS than mastectomy after correction for all identifiable confounders. Superior survival for BCT was seen both after long-term follow-up (1999-2005 cohort) and in the era of more contemporary adjuvant systemic therapy (2006-2012 cohort). In the 1999-2005 cohort, BCT showed superior BCSS in all subgroups based on age, stage, adjuvant systemic therapy and comorbidity. In the 2006-2012 cohort, BCT showed superior BCSS for all T1-2N0-1 staged patients > 50 years, and the effect was even seen in patients with comorbidity. In patients treated with chemotherapy, irrespective of hormonal and HER2 receptor status, BCT was similar to mastectomy.
Our results further support the hypothesis that BCT might be the preferred choice for breast cancer patients when both BCT and mastectomy are suitable treatment options. [5] [6] [7] [8] [9] [10] 12 A previous observational study that also investigated survival outcomes following both types of surgery hypothesized that the prognostic advantage of BCT over mastectomy may be related to the effects of RT as a component of BCT while early stage mastectomy patients in general receive no RT5. This explanation is partly supported by the results of our study, as the survival differences were most pronounced in the subgroups where a lower percentage of patients was treated with RT in the mastectomy group, while all patients in the BCT group received RT. Since patients with N1 stage were more often treated with adjuvant systemic therapy, survival differences between BCT and mastectomy can also be influenced by the use of adjuvant systemic therapy. In the most recent cohort, we found a larger benefit of BCT for T1N0 patients as compared to T1N1 stage. This might be explained by an increased utilization rate of RT after mastectomy for N1 disease over time, following the publication of level 1 evidence supporting PMRT for patients with limited nodal involvement as well. 20 In that case, the benefit of RT for N1 disease after mastectomy could have blurred the benefit of BCT. In contrast, we observed a larger benefit of BCT for T2N1 stage as compared to T2N0 stage. Importantly, these patients are more likely to receive adjuvant systemic therapy. The interplay between systemic therapy and RT is very complex, 21 resulting in the fact that the possible benefit of RT is not always more pronounced in N0 stage compared to N1 stage. To make sure that the lateralization of the tumor did not affect the survival estimates, we conducted a sensitivity analyses in which we stratified the analyses by lateralization (left or right). This did not change the results (data not shown). From previous studies we know that adjuvant systemic therapy largely influences survival rates. 22, 23 In the 1999-2005 cohort, the superior effect of BCT remained after stratification for use and type of adjuvant systemic therapy. However, in the 2006-2012 cohort, BCT and mastectomy showed similar BCSS and OS in patients treated with chemotherapy and similar BCSS for patients treated with both chemotherapy and endocrine therapy. We hypothesize that especially the contemporary chemotherapy regimens diminish the survival advantage of BCT over mastectomy. Similar BCSS and OS for BCT and mastectomy in patients < 50 years in the 2006-2012 cohort support this hypothesis, since in both cohorts over 80% of the patients < 40 and over 60% of the patients 40-49 years received chemotherapy (Supporting Information Tables S3 and S4 ). In the current era of personalized medicine, targeted therapy plays an important role in treatment strategies. Targeted therapy is in our analyses included in the chemotherapy variable, since in The Netherlands, it is given simultaneously with chemotherapy in HER2 positive patients. In this way, we avoided collinearity in the multivariable analysis. However, by doing this we were not able to investigate the direct effect of targeted therapy alone, a indirect analysis, stratifying for HER2 status, showed the advantage of BCT over MAST in both HER2 positive and negative patients (Supporting Information Table S6 ). The result that BCT and mastectomy lead to similar survival outcomes in patients < 40 years is supported by other observational studies that reported minor survival differences between BCT and mastectomy in patients < 40 years. [24] [25] [26] In the T1-2N2 stages we also observed similar BCSS for BCT and mastectomy. This may be explained by the fact that 83.8% and 70.2% of these patients received adjuvant systemic therapy, in the BCT and mastectomy group, respectively. However, it may also be explained by the use of postmastectomy radiation therapy (PMRT), since 85.7% of the patients in the mastectomy group had undergone PMRT (data not shown). For patients with comorbidity, a large survival advantage for BCT compared to mastectomy was observed in both cohorts. For the cohort with known comorbidity status, the baseline characteristics and the proportion of BCT was approximately similar to the entire cohort, making this subcohort representative. These results confirm that BCT is safe and possibly the preferred option even in patients with comorbidity when both treatments are suitable. In patients without comorbidity, we did not find a significant difference between BCT and mastectomy on BCSS in the 2006-2012 cohort, but we did find improved long-term BCSS for BCT compared to mastectomy in the 1999-2005 cohort.
The fact we did not find a significant difference between BCT and mastectomy in patients without comorbidities in the 2006-2012 cohort may be explained by the age distributions. Patients without comorbidities are generally younger than patients with comorbidities (as is also seen in our data). In patients < 50 years we did not observe survival differences after BCT and mastectomy, while we did find increased BCSS for BCT compared to mastectomy in patients > 50 years.
The similar BCSS after BCT or mastectomy in patients without comorbidity confirms results of large RCTs. [1] [2] [3] [4] It is expected that participants in RCTs are mainly patients without comorbidity and thus this subgroup probably best resembles patients studied in these RCTs.
A possible explanation for the differences in BCSS between the two time cohorts, apart from the difference in the applied chemotherapy regimens, is the length of followup. Recurrence peaks (including local/locoregional recurrences and distant metastases) are described to occur 2, 5 and 9 years after diagnosis. Since the 2006-2012 cohort had a median follow-up of 7 years, this cohort may have had too short follow-up to reveal the effect of BCT and mastectomy after 7 years. Another explanation is the fact that diagnostic procedures and treatments (surgery, RT and adjuvant systemic therapy) have improved over time, which may have influenced the generalizability of the treatment effects. However, this is largely obviated by analysis of the two time cohorts separately. Of note, the aim of this study was to investigate the effect of BCT compared to mastectomy after long-term follow-up, and in the era of more contemporary diagnostics and adjuvant treatment, and not to compare the two cohorts over time by itself.
Major strengths of this study are its population-based character, the large number of patients, the availability of data on cause of death, stratification for age, stage, hormonal and HER2 receptor status, adjuvant systemic therapy and comorbidity. By linking the NCR registry to the CBS registry -both covering the entire population -data on cause of death could be collected for almost all deceased patients. The population-based character increases the generalizability of the results and is therefore of additional value to results that are obtained through large RCTs, in which selected populations are studied. 30 Since age, stage, hormonal and HER2 receptor status, adjuvant systemic therapy and comorbidity are considered to be the most important variables that could potentially bias the analysis for survival differences between BCT and mastectomy, the stratified analyses gave more insight in treatment effects for these specific subgroups. As a result, we were able to identify subgroups that would benefit the most from BCT. A limitation of this study is that comorbidity status was only known for a relatively small percentage of patients, resulting in a low number of events, disabling us from doing stratified analyses within the group of patients with comorbidity. Although data on comorbidity was only available for a subcohort of patients, this subcohort had similar baseline characteristics and was thus considered representative for the entire cohort. Another limitation of this study is its observational design, in which confounding by severity and residual confounding cannot be excluded. Furthermore, a causal relationship explaining the superior outcome for BCT cannot be confirmed based on observational studies only. In this study, patients were treated with BCT or mastectomy with or without RT. Since patients treated with PMRT may have a poorer prognosis compared to patients treated with mastectomy only, we might have created confounding by severity. To largely overcome this problem, we performed a subanalysis in T1-2N0-1 breast cancer excluding patients treated with RT following mastectomy (PMRT). This led to similar favorable BCCS and OS rates for BCT compared to mastectomy in all T and N stages (data not shown). There is a considerable debate with regard to the value of observational studies in the evaluation of treatment outcome as compared to randomized trials. Population-based observational studies may increase our knowledge concerning treatment effects in daily practice. Although these studies can be extremely informative, results have to be interpreted with care and residual confounding is unavoidable. For sufficient interpretation of treatment decisions, the current leading national guidelines should be considered. Another limitation is the lack of data on the extent of RT. A discrimination between local or locoregional RT was not registered and could therefore not be analyzed. Furthermore, we lacked data on comorbidities occurring during follow-up.
Clinical impact
Within this cohort, the superior survival of BCT compared to mastectomy in T1-2N0-1 breast cancer is confirmed. We identified several subgroups that benefit most from BCT. Importantly, superior BCSS for BCT was observed in patients >50 years and patients with comorbidity at diagnosis. Therefore, for older patients and patients with comorbidity it is no longer an argument to prefer mastectomy over BCT. However, in case of an expected inferior aesthetic outcome following BCT, or a contra-indication for RT, mastectomy may still be the best treatment option. These results could add as an additional argument for BCT in shared (surgical) decisionmaking when both treatments are suitable options.
Conclusion
BCT is the preferred treatment option in T1-2N0-1 stage breast cancer. Subgroups that may benefit most from BCT (when both treatments are suitable) are patients > 50 years, patients with comorbidity and those not treated with chemotherapy, irrespective of hormonal or HER2 receptor status. We confirmed this both after long-term follow-up and in the era of modern diagnostics and adjuvant systemic therapy.
